8-KMaterial Agreements

REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Jul 1, 2005)

Filed July 1, 2005For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) announced an amendment to its Focused Collaboration Agreement with The Procter & Gamble Company (P&G). The amendment, effective June 30, 2005, prematurely terminates the research activities under the agreement, six months ahead of its scheduled expiration. This termination marks the completion of the research phase of the collaboration. Under the terms of the amendment, P&G will provide Regeneron with approximately $8.4 million to fulfill its remaining research funding obligations. Regeneron, in turn, will pay P&G $950,000 to acquire certain capital equipment. The agreement also details the division of rights to research programs and pre-clinical product candidates. Notably, Regeneron will be entitled to royalties on future product sales of a P&G pre-clinical candidate, but not for any other products arising from the collaboration. Neither party will participate in the development or commercialization of the other's product candidates.

Key Highlights

  • 1Early termination of research activities under the Focused Collaboration Agreement with Procter & Gamble (P&G), effective June 30, 2005.
  • 2P&G to make a final payment of approximately $8.4 million to Regeneron for remaining research funding.
  • 3Regeneron to pay P&G $950,000 for the acquisition of specific capital equipment.
  • 4Division of rights to research programs and pre-clinical product candidates developed during the collaboration.
  • 5Regeneron eligible to receive royalties on future sales of one specific P&G pre-clinical candidate.
  • 6Neither party will have rights to participate in the development or commercialization of the other's product candidates.

Frequently Asked Questions

The primary financial impact is Regeneron receiving approximately $8.4 million from P&G to cover remaining research funding, while paying out $950,000 for capital equipment. This results in a net inflow of funds from the termination of the research phase.

Regeneron's future revenue opportunities are limited to potential royalties based on any future product sales arising from one specific pre-clinical candidate developed by P&G during the collaboration. No other products from the collaboration are expected to generate royalties for Regeneron.

The early termination signifies the completion of the research phase of the collaboration between Regeneron and P&G, six months prior to the original expiration date of December 31, 2005. It indicates a conclusion to joint research efforts.

No, the amendment clearly states that neither party has the right to participate in the development or commercialization of the other party’s product candidates moving forward. The collaboration's research phase is concluded, and rights have been divided.